Literature DB >> 20179898

Sulphated galactosylceramide.

K Buschard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20179898     DOI： 10.1007/s00125-010-1690-3

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  8 in total

1.  Molecular cloning and characterization of a human beta-Gal-3'-sulfotransferase that acts on both type 1 and type 2 (Gal beta 1-3/1-4GlcNAc-R) oligosaccharides.

Authors:  K Honke; M Tsuda; S Koyota; Y Wada; N Iida-Tanaka; I Ishizuka; J Nakayama; N Taniguchi
Journal:  J Biol Chem       Date:  2001-01-05       Impact factor: 5.157

2.  Ceramides: a new player in the inflammation-insulin resistance paradigm?

Authors:  J M R Gill; N Sattar
Journal:  Diabetologia       Date:  2009-10-03       Impact factor: 10.122

Review 3.  Involvement of sulfatide in beta cells and type 1 and type 2 diabetes.

Authors:  K Buschard; M Blomqvist; T Osterbye; P Fredman
Journal:  Diabetologia       Date:  2005-09-06       Impact factor: 10.122

4.  Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease.

Authors:  V D F de Mello; M Lankinen; U Schwab; M Kolehmainen; S Lehto; T Seppänen-Laakso; M Oresic; L Pulkkinen; M Uusitupa; A T Erkkilä
Journal:  Diabetologia       Date:  2009-08-11       Impact factor: 10.122

5.  Molecular cloning, chromosomal mapping, and characterization of the mouse UDP-galactose:ceramide galactosyltransferase gene.

Authors:  T Coetzee; X Li; N Fujita; J Marcus; K Suzuki; U Francke; B Popko
Journal:  Genomics       Date:  1996-07-01       Impact factor: 5.736

6.  Sulfatide increases adiponectin and decreases TNF-alpha, IL-6, and IL-8 in human adipose tissue in vitro.

Authors:  Jens M Bruun; Allan Roeske-Nielsen; Bjørn Richelsen; Pam Fredman; Karsten Buschard
Journal:  Mol Cell Endocrinol       Date:  2006-11-09       Impact factor: 4.102

7.  Low serum concentration of sulfatide and presence of sulfated lactosylceramid are associated with Type 2 diabetes. The Skaraborg Project.

Authors:  K Buschard; P Fredman; E Bøg-Hansen; M Blomqvist; J Hedner; L Råstam; U Lindblad
Journal:  Diabet Med       Date:  2005-09       Impact factor: 4.359

8.  Beta-galactosylceramide increases and sulfatide decreases cytokine and chemokine production in whole blood cells.

Authors:  A Roeske-Nielsen; P Fredman; J E Mansson; K Bendtzen; K Buschard
Journal:  Immunol Lett       Date:  2004-02-15       Impact factor: 3.685
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.